SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Charles Hill who wrote (172)12/18/1997 6:34:00 PM
From: shdu  Read Replies (2) of 656
 
Charles,

I did not know it was the same analyst. He was correct last time when he questioned the clinical trial results though. He must have read the article regarding pitfalls of Enbrel trial on New England Journal of Medicine before it was published, since he downgraded the stock a week before based on exactly the same reasons. I thought the questions brought upon by the authors of that article were logical. In any case, he probably knows medicine pretty well and may have more contacts than most of us. I hope that Hoest can disclose the information of their new drug soon.

Sam

>>Sam --- I share your frustration here. No public information. I am a little suspicious about this whole thing, given that the same Montgomery analyst who issued the sell rating on IMNX a few weeks back is also the one gushing about how great the Hoest drug is. If the Hoest drug is so great, why is there not more news on it?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News